A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
Clinical Trial Grant
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Novo Nordisk, Inc.
Start Date
February 10, 2025
End Date
April 30, 2027
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Novo Nordisk, Inc.
Start Date
February 10, 2025
End Date
April 30, 2027